References
- Obesity and cancer fact sheet - National Cancer Institute [Internet]. 2020 [cited 2021 Feb 8]. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet
- CDC. Adult Obesity [Internet]. Centers for Disease Control and Prevention. 2021 [cited 2021 Feb 8]. Available from: https://www.cdc.gov/obesity/adult/causes.html
- van Rijswijk A-S, van Olst N, Schats W, et al., What is weight loss after bariatric surgery expressed in percentage Total Weight Loss (%TWL)? A Systematic Review. Obes Surg, Internet]. 2021 May 17 [cited 2021 Jun 15]; Available from… https://doi.org/10.1007/s11695-021-05394-x
- Kang JH, Le QA. Effectiveness of bariatric surgical procedures. Medicine (Baltimore) Internet]. 2017 Nov 17 [cited 2021 Feb 11];96(46). Available from. [];():e8632. : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704829/
- Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–234.
- Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity. Lancet. 2016 May;387(10031):1947–1956.
- Lucchetta RC, Riveros BS, Pontarolo R, et al. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Clinics. 2017 May;72(5):317–324. .
- Lobstein CT, Brinsden H We are grateful for the compilers of online databases and information on obesity especially the World Health Organization’s Global Health Observatory, the NCD risk factor collaboration based at Imperial College London and OECD. Please see the Data Sources section of this report in Appendix 1 for more details. 2025;242.
- Kelly T, Yang W, Chen C-S, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 1986;10(6):7.
- Facts & figures [Internet]. [ cited 2021 Jan 22]. Available from: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
- Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ. 2012 Jan;42(Supplement 1):S90–S102.
- Shekar M, Popkin B. Obesity: health and economic consequences of an impending global challenge [Internet]. Washington, DC: World Bank; 2020 [cited 2021 Feb 8]. Available from: http://hdl.handle.net/10986/32383
- Zeng Q, Li N, Pan X-F, et al. Clinical management and treatment of obesity in China. Lancet Diabetes Endocrinol. 2021 Jun 1;9(6):393–405.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015 Jul 2;373(1):11–22.
- Novo Nordisk’s Saxenda remains world’s top obesity treatment [Internet]. KBR. 2020 [cited 2021 Mar 11]. Available from: http://www.koreabiomed.com/news/articleView.html?idxno=7768
- Nauck MA, Meier JJ. MANAGEMENT OF ENDOCRINE DISEASE: are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019 Dec;181(6):R211–34.
- Brandt SJ, Götz A, Tschöp MH, et al. Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides. 2018 Feb;100:190–201.
- Hinnen D. Glucagon-Like Peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr Publ Am Diabetes Assoc. 2017 Aug; 30(3):202–210. .
- Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways.JCI Insight, Internet. cited 2021 Mar 10];5(6). Available from . (). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213778/
- Moonschi FH, Hughes CB, Mussman GM, et al. Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells. Acta Diabetol. 2018 May 1;10(4):902–905.
- Johansson KS, Sonne DP, Knop FK, et al. What is on the horizon for type 2 diabetes pharmacotherapy? – an overview of the antidiabetic drug development pipeline. Expert Opin Drug Discov. 2020 Nov 1;15(11):1253–1265.
- Nordisk N, following in Lilly’s Trulicity footsteps, files higher Ozempic dose for diabetes [Internet]. FiercePharma. [ cited 2021 Jun 15]. Available from: https://www.fiercepharma.com/marketing/novo-nordisk-following-lilly-s-trulicity-footsteps-files-ozempic-higher-dose-for-diabetes
- Lingvay I, Hansen T, Macura S, et al. Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ Open Diabetes Res Care. 2020 Oct 28;8(2):e001706. Internet]. [cited 2021 Jun 15];(). Available from. .
- Nathan BM, Rudser KD, Abuzzahab MJ, et al. Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity. Clin Obes. 2016 Feb;6(1):73–78. .
- Ahrén B, Atkin SL, Charpentier G, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018 Sep;20(9):2210–2219. .
- Aroda VR. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab. 2018 Jan 24;20:22–33. .
- Storgaard H, Cold F, Gluud LL, et al. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017 Jun 1;19(6):906–908.
- Taylor SI, Taylor SI. GLP-1. GLP-1 receptor agonists: differentiation within the class. Lancet Diabetes Endocrinol. 2018 Feb;6(2):83. .
- Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018 Feb 1;6(2):105–113.
- Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct 1;7(10):776–785. .
- Theilade S, Christensen MB, Vilsbøll T, et al. An overview of obesity mechanisms in humans: endocrine regulation of food intake, eating behaviour and common determinants of body weight. 19.
- Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180–2193.
- Sparre‐Ulrich AH, Hansen LS, Svendsen B, et al. Species-specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br J Pharmacol. 2016 Jan;173(1):27–38. .
- Killion EA, Wang J, Yie J, et al. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med. 2018 Dec 19;10(472):eaat3392. Internet]. [cited 2021 Mar 11];(). Available from. .
- Duncan RE, Ahmadian M, Jaworski K, et al. Regulation of Lipolysis in Adipocytes [Internet]. https://doi.org/10.1146/annurev.nutr.27.061406.093734. 2007 [cited 2021 Jan 27]. Available from: https://www.annualreviews.org/doi/abs/10.1146/annurev.nutr.27.061406.093734
- Billington CJ, Briggs JE, Link JG, et al., Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo. Am J Physiol-Regul Integr Comp Physiol, Internet. 1991 Aug 1 cited 2021 Jan 27. Available from:. https://journals.physiology.org/doi/abs/10.1152/ajpregu.1991.261.2.R501 261(2): R501–R507.
- Kinoshita K, Ozaki N, Takagi Y, et al. Glucagon is essential for adaptive thermogenesis in brown adipose tissue. Endocrinology. 2014 Sep 1;155(9):3484–3492.
- Petersen KM, Bøgevig S, Riis T, et al. High-dose glucagon has hemodynamic effects regardless of cardiac beta-adrenoceptor blockade: a randomized clinical trial. J Am Heart Assoc. Internet]. 2020 Nov 3 [cited 2021 Apr 11]; Available from. ;9(21). []. https://www.ahajournals.org/doi/abs/10.1161/JAHA.120.016828
- Mathiesen DS, Bagger JI, Bergmann NC, et al. The effects of dual GLP-1/GIP receptor agonism on glucagon secretion—A review. Int J Mol Sci. Internet]. 2019 Sep [cited 2021 Apr 11];21(1). Available from []; ():4092. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747202/
- Pocai A. Action and therapeutic potential of oxyntomodulin. Mol Metab. 2014 Jun;3(3):241.
- Pocai A. Unraveling oxyntomodulin, GLP1’s enigmatic brother. J Endocrinol. 2012 Dec 1;215(3):335–346.
- Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003 Oct 1;88(10):4696–4701.
- Perakakis N, Kokkinos A, Peradze N, et al. Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: evidence from two independent trials. Metab - Clin Exp [Internet]. 2019 Dec 1 [cited 2021 Jan 27];101. Available from: https://www.metabolismjournal.com/article/S0026-0495(19)30212-4/abstract
- Wynne K, Park AJ, Small CJ, et al. Subcutaneous Oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005 Aug 1;54(8):2390–2395.
- Fu W, Patel A, Jhamandas JH. Amylin receptor: a common pathophysiological target in alzheimer’s disease and diabetes mellitus. Front Aging Neurosci Available from:. 2013 cited 2013 Jan 27;13:5. Internet: https://www.frontiersin.org/articles/10.3389/fnagi.2013.00042/full
- Lutz TA. Control of food intake and energy expenditure by amylin—therapeutic implications. Int J Obes. 2009 Apr;33(S1):S24–7.
- Larsen AT, Sonne N, Andreassen KV, et al. The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy. J Pharmacol Exp Ther. 2019 Jul 1;370(1):35–43.
- Jorsal T, Rungby J, Knop FK, et al. GLP-1 and amylin in the treatment of obesity. Curr Diab Rep. 2016 Jan 1;16(1):1–7.
- Hieronymus L, Griffin S. Role of amylin in type 1 and Type 2 Diabetes. Diabetes Educ. 2015 Dec 1;41(1_suppl):47S–56S.
- Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2011 Feb 1;13(2):169–180.
- Association AD. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care. 2019 Jan 1;42(Supplement 1): S90–102. .
- Smith SR, Aronne LJ, Burns CM, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008 Sep 1;31(9):1816–1823.
- Meek CL, Lewis HB, Reimann F, et al. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides. 2016 Mar;77(77):28–37.
- Laferrère B. Bariatric surgery and obesity: influence on the incretins. Int J Obes Suppl. 2016 Dec;6(Suppl S1):S32–6.
- Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes. 2009 Jul;33(7):786–795. .
- Behary P, Tharakan G, Alexiadou K, et al. Combined GLP-1, Oxyntomodulin, and Peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes: a randomized, single-blinded, placebo-controlled study. Diabetes Care. 2019 Aug 1;42(8):1446–1453.
- Brandt SJ, Kleinert M, Tschöp MH, et al. Are peptide conjugates the golden therapy against obesity? J Endocrinol. 2018 May 30;238(2):R109–19.
- Hasib A. Multiagonist unimolecular peptides for obesity and type 2 diabetes: current advances and future directions. Clin Med Insights Endocrinol Diabetes. 2020 Jan 1;13:1179551420905844. .
- Bhat VK, Kerr BD, Vasu S, et al. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice. Diabetologia. 2013 Jun 1;56(6):1417–1424.
- Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015 Jan;10(472):27–36. .
- Saxena A, Gorman D, Chidsey K, et al. 353-OR: oral small molecule GLP-1R Agonist PF-06882961 robustly reduces plasma glucose and body weight after 28 days in adults with T2DM. Diabetes Internet]. 2020 Jun 1 [cited 2021 Jan 29];69(Supplement 1). Available from. [];():353–OR. : https://diabetes.diabetesjournals.org/content/69/Supplement_1/353-OR
- PF-06882961 | GLP-1R Agonist | medChemExpress [Internet]. MedchemExpress.com. [ cited 2021 Jan 29]. Available from: https://www.medchemexpress.com/pf-06882961.html
- Pipeline and Clinical Trials | pfizer [Internet]. [ cited 2021 Jan 29]. Available from: https://www.pfizer.com/science/internal-medicine/pipeline
- Griffith DA, Edmonds DJ, Fortin J-P, et al. A small-molecule oral agonist of the human glucagon-like peptide-1 receptor. bioRxiv. 2020 Sep 30. 2020.09.29.319483
- Pfizer. A 16-WEEK, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE [Internet]. clinicaltrials.gov; 2021 Jan [cited 2021 Jan 27]. Report No.: NCT03985293. Available from: https://clinicaltrials.gov/ct2/show/NCT03985293
- Pfizer. A 26-WEEK, PHASE 2B, 2-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06882961 ADMINISTRATION IN ADULTS WITH OBESITY [Internet]. clinicaltrials.gov; 2021 Feb [cited 2021 Feb 14]. Report No.: NCT04707313. Available from: https://clinicaltrials.gov/ct2/show/NCT04707313
- Li C, Yang M, Wang X, et al. Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites. Biochem Pharmacol. 2018 Apr 1;150:46–53. .
- Gmax long-acting GLP-1R agonist has been approved by the China Human Genetic Resources Management to start clinical trials [Internet]. [ cited 2021 Feb 15]. Available from: http://www.gmaxbiopharm.com/news_detail/23.html
- GMA105 [Internet]. [ cited 2021 Jan 29]. Available from: http://www.gmaxbiopharm.com/wap_product_detailen/id/3.html
- GMAX Zhengzhou manufacturing site breaks ground [Internet]. [ cited 2021 Feb 15]. Available from: http://www.gmaxbiopharm.com/news_detail/30.html
- Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015 Sep 24;155(9):3484–3492.
- Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP Trials 1 to 5. Obesity. 2020 Jun 1;28(6):1050–1061. .
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021 Feb 10;384(11):NEJMoa2032183. .
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar;397(10278):971–984. .
- Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA, Internet]. 2021 Feb 24 [cited 2021 Apr 9]; Available from … . https://jamanetwork.com/journals/jama/fullarticle/2777025 325(14): 1403.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, Internet]. 2021 Mar 23 [cited 2021 Apr 9]; Available from … . https://jamanetwork.com/journals/jama/fullarticle/2777886 325(14): 1414.
- Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019 Jul 1;13(7):528–539.
- Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019 Jul 6;394(10192):39–50.
- Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 Trial. Diabetes Care. 2019 Dec 1;42(12):2272–2281.
- News Details [Internet]. [ cited 2021 Jun 10]. Available from: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=62112
- A quick guide to the STEP trials [Internet]. diabetes.medicinematters.com. 2021 [cited 2021 Apr 10]. Available from: https://diabetes.medicinematters.com/semaglutide/obesity/quick-guide-step-trials/18854832
- Pipeline – therapeutic Portfolio | carmot Therapeutics [Internet]. [ cited 2021 Jan 29]. Available from: https://carmot-therapeutics.us/pipeline/
- Carmot therapeutics expands leadership team and closes $47 million series c financing to advance novel incretin receptor modulators through phase 2 studies [Internet]. 2020 [cited 2021 Mar 3]. Available from: https://www.businesswire.com/news/home/20200930005254/en/Carmot-Therapeutics-Expands-Leadership-Team-and-Closes-47-Million-Series-C-Financing-to-Advance-Novel-Incretin-Receptor-Modulators-Through-Phase-2-Studies
- CT 868 - AdisInsight [Internet]. [ cited 2021 Jan 29]. Available from: https://adisinsight.springer.com/drugs/800053575
- Amgen Pipeline [Internet]. [ cited 2021 Feb 15]. Available from: https://www.amgenpipeline.com
- Amgen. A Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 133 in subjects with obesity [Internet]. clinicaltrials.gov; 2021 Feb [cited 2021 Feb 14]. Report No.: NCT04478708. Available from: https://clinicaltrials.gov/ct2/show/NCT04478708
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab, 2018 Dec 1. 33: 3–14.
- Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. Internet]. 2020 Sep 3 [cited 2021 Mar 2];5(17). Available from. ;(). []. https://insight.jci.org/articles/view/140532#B9
- Lilly’s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes | eli Lilly and Company [Internet]. [ cited 2021 Mar 2]. Available from: https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-significantly-reduced-a1c-and-body-weight
- Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly’s SURPASS program | eli Lilly and Company [Internet]. [ cited 2021 Mar 2]. Available from: https://investor.lilly.com/news-releases/news-release-details/tirzepatide-significantly-reduced-a1c-and-body-weight-people
- Eli Lilly and Company. A randomized, placebo-controlled, parallel-arm study to investigate the effect of once-weekly tirzepatide on energy expenditure and food intake in obese subjects [Internet]. clinicaltrials.gov; 2021 Mar [cited 2021 Mar 22]. Report No.: NCT04081337. Available from: https://clinicaltrials.gov/ct2/show/NCT04081337
- Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013 Oct 30;5(209):209ra151–209ra151.
- OPK88003 (Oxyntomodulin Analog) [Internet]. OPKO Health, Inc. [ cited 2021 Feb 5]. Available from: https://www.opko.com/what-we-do/our-research/opk88003-oxyntomodulin-analog
- SEC. Opko Health, Inc. 2017 Current Report 8-K [Internet]. SEC.report. [cited 2021 Apr 11]. Available from: https://sec.report/Document/0001193125-17-278635/
- OPKO announces positive topline results in phase 2 diabetes and obesity trial Nasdaq: OPK[Internet]. [ cited 2021 Feb 5]. Available from: https://www.globenewswire.com/news-release/2019/03/21/1758475/0/en/OPKO-Announces-Positive-Topline-Results-In-Phase-2-Diabetes-And-Obesity-Trial.html
- Lipolytic and insulinotropic effects of HM12525A, a novel long-acting GLP-1/glucagon dual agonist - Virtual Meeting | EASD [Internet]. [ cited 2021 Mar 9]. Available from: https://www.easd.org/virtualmeeting/home.html#!resources/lipolytic-and-insulinotropic-effects-of-hm12525a-a-novel-long-acting-glp-1-glucagon-dual-agonist--2
- Herald TK Hanmi’s once returned pipeline finds new partner in US [Internet]. 2020 [cited 2021 Feb 5]. Available from: http://www.koreaherald.com/view.php?ud=20200804000917
- Ingelheim B. A phase I, blinded within dose groups, multiple dose, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of different titration schemes of bi 456906 in patients with obesity and overweight. [Internet]. clinicaltrials.gov; 2020 May [cited 2021 Feb 4]. Report No.: NCT03591718. Available from: https://clinicaltrials.gov/ct2/show/NCT03591718
- A study to test how different doses of BI 456906 are tolerated in Japanese men with a Body Mass Index (BMI) Between 23 and 40 kg/m2 - no study results posted - ClinicalTrials.gov [Internet]. [ cited 2021 Feb 16]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT04384081
- Ingelheim B, Pharma Z Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to phase 2 clinical testing in obesity/diabetes [Internet]. boehringer-ingelheim.us. [ cited 2021 Feb 5]. Available from: https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-and-zealand-pharma-advance-dual-acting-glp-1glucagon-agonist-bi
- Ingelheim B. A Phase II, randomized, parallel group, dose-finding study of subcutaneously Administered BI 456906 for 16 weeks, compared with placebo and open-label semaglutide in patients with type 2 diabetes mellitus. [Internet]. clinicaltrials.gov; 2021 Feb [cited 2021 Feb 4]. Report No.: NCT04153929. Available from: https://clinicaltrials.gov/ct2/show/NCT04153929
- BI 456906 - AdisInsight [Internet]. [ cited 2021 Feb 16]. Available from: https://adisinsight.springer.com/drugs/800049709
- Ambery PD, Klammt S, Posch MG, et al. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study. Br J Clin Pharmacol. 2018 Oct 1;84(10):2325–2335.
- Usui R, Yabe D, Seino Y. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity. J Diabetes Investig. 2019 Jul;10(4):902–905.
- Ambery P, Parker VE, Stumvoll M, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018 Jun 30;391(10140):2607–2618.
- Oral Abstracts (Abstracts 1–288). Hepatology. 2019;70(S1):1–187.
- EASL46e83dfb644c | meta-dcr [Internet]. [ cited 2021 Apr 11]. Available from: https://easl-46e83dfb644c.meta-dcr.com/dilc2020/crs/effects-of-cotadutide-on-biomarkers-of-nonalcoholic-steatohepatitis-in-overweight-or-obese-subjects-with-type-2-diabetes-mellitus-a-54-week-analysis-of-a-randomized-phase-2b-study
- MedImmune LLC A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and pharmacodynamic effects of MEDI0382 in obese subjects with non-alcoholic fatty liver disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH) [Internet]. clinicaltrials.gov; 2021 Mar [cited 2021 Mar 8]. Report No.: NCT04019561. Available from: https://clinicaltrials.gov/ct2/show/NCT04019561
- Tillner J, Posch MG, Wagner F, et al. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes Metab. 2019 Jan 1;21(1):120–128.
- Sanofi. A 26-week randomized, double-blind, placebo-controlled, dose-ranging phase 2 study to assess the safety and efficacy of SAR425899 in patients with type 2 diabetes mellitus [Internet]. clinicaltrials.gov; 2021 Jan [cited 2021 Mar 1]. Report No.: results/NCT02973321. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02973321
- A preliminary study of the efficacy and safety of MK-8521 for Type 2 Diabetes (MK-8521-004) - Study Results - ClinicalTrials.gov [Internet]. [ cited 2021 Feb 15]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02492763
- R&D pipeline [Internet]. [ cited 2021 Jan 28]. Available from: https://www.novonordisk.com/science-and-technology/r-d-pipeline.html
- Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021 May 8;397(10286):1736–1748.
- A/S NN. Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity [Internet]. GlobeNewswire News Room. 2020 [cited 2021 Feb 10]. Available from: http://www.globenewswire.com/news-release/2020/06/18/2050266/0/en/Novo-Nordisk-successfully-completes-AM833-phase-2-trial-and-phase-1-combination-trial-with-AM833-and-semaglutide-in-obesity.html
- Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP tri-agonist (HM15211) - Virtual Meeting | EASD [Internet]. [ cited 2021 Mar 9]. Available from: https://www.easd.org/virtualmeeting/home.html#!resources/potent-body-weight-loss-and-therapeutic-efficacy-in-a-nash-animal-model-by-a-novel-long-acting-glp-1-glucagon-gip-tri-agonist-hm15211
- Pipeline | r&D [Internet]. [ cited 2021 Jan 29]. Available from: https://www.hanmipharm.com/ehanmi/handler/Rnd-FocusedPipelineB
- LAPSCOVERY | technology | r&D [Internet]. [ cited 2021 Jan 29]. Available from: https://www.hanmipharm.com/ehanmi/handler/Rnd-ProjectLapscovery
- Neuroprotective effects of HM15211, a novel long-acting GLP-1/Glucagon/GIP tri-agonist in the MPTP Parkinson’s disease mouse model - Virtual Meeting | EASD [Internet]. [ cited 2021 Mar 9]. Available from: https://www.easd.org/virtualmeeting/home.html#!resources/neuroprotective-effects-of-hm15211-a-novel-long-acting-glp-1-glucagon-gip-tri-agonist-in-the-mptp-parkinson-s-disease-mouse-model-d9fa2815-9fb4-4109-aa0f-bf029c92dcd2
- HM 15211 - AdisInsight [Internet]. [ cited 2021 Jan 29]. Available from: https://adisinsight.springer.com/drugs/800049366
- Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity - Full Text View - ClinicalTrials.gov [Internet]. [ cited 2021 Jan 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03661879
- Obesity: EU research battles the bulge | research*eu Magazine | issue 84 | CORDIS | European Commission [Internet]. [ cited 2021 May 2]. Available from: https://cordis.europa.eu/article/id/402027-obesity-eu-research-battles-the-bulge
- Jph W,SJ, Cardiovascular outcome trials in obesity: a review. Obes Rev Off J Int Assoc Study Obes. Internet]. 2021 Jan [cited 2021 May 2];22(1). Available from . (). https://pubmed.ncbi.nlm.nih.gov/32893459/
- Semaglutide effects on heart disease and stroke in patients with overweight or obesity - full text view - ClinicalTrials.gov [Internet]. [ cited 2021 May 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03574597
- Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® [Internet]. MidgardFinance.com. 2020 [cited 2021 Feb 11]. Available from: https://blog.midgardfinance.com/2020/08/06/novo-nordisk-grows-glp-1-market-share-in-the-us-with-ozempic-and-rybelsus/
- Jp W, Rv O, Lv J, et al. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes MetabInternet]. 2016 May [cited 2021 May 2];18(5). Available from. ; (). . : https://pubmed.ncbi.nlm.nih.gov/26833744/
- Jp F, E B, L NR, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). diabetes care [Internet]. 2021 Mar cited 2021 May 2. 44(3) Available from. https://pubmed.ncbi.nlm.nih.gov/33397768/
- Bergmann NC, Lund A, Gasbjerg LS, et al. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia. 2019;62(4):665–675. .
- GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys. Cell Rep Med. 2021, Apr. 30: 100263.